Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer

The oncogenic receptor tyrosine kinase (RTK) ERBB2 is known to dimerize with other EGFR family members, particularly ERBB3, through which it potently activates PI3K signalling. Antibody-mediated inhibition of this ERBB2/ERBB3/PI3K axis has been a cornerstone of treatment for ERBB2-amplified breast c...

Full description

Saved in:
Bibliographic Details
Published inBreast cancer research : BCR Vol. 21; no. 1; p. 43
Main Authors Kennedy, Sean P, Han, Jeremy Z R, Portman, Neil, Nobis, Max, Hastings, Jordan F, Murphy, Kendelle J, Latham, Sharissa L, Cadell, Antonia L, Miladinovic, Dushan, Marriott, Gabriella R, O'Donnell, Yolande E I, Shearer, Robert F, Williams, James T, Munoz, Amaya Garcia, Cox, Thomas R, Watkins, D Neil, Saunders, Darren N, Timpson, Paul, Lim, Elgene, Kolch, Walter, Croucher, David R
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 21.03.2019
BioMed Central
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The oncogenic receptor tyrosine kinase (RTK) ERBB2 is known to dimerize with other EGFR family members, particularly ERBB3, through which it potently activates PI3K signalling. Antibody-mediated inhibition of this ERBB2/ERBB3/PI3K axis has been a cornerstone of treatment for ERBB2-amplified breast cancer patients for two decades. However, the lack of response and the rapid onset of relapse in many patients now question the assumption that the ERBB2/ERBB3 heterodimer is the sole relevant effector target of these therapies. Through a systematic protein-protein interaction screen, we have identified and validated alternative RTKs that interact with ERBB2. Using quantitative readouts of signalling pathway activation and cell proliferation, we have examined their influence upon the mechanism of trastuzumab- and pertuzumab-mediated inhibition of cell growth in ERBB2-amplified breast cancer cell lines and a patient-derived xenograft model. We now demonstrate that inactivation of ERBB3/PI3K by these therapeutic antibodies is insufficient to inhibit the growth of ERBB2-amplified breast cancer cells. Instead, we show extensive promiscuity between ERBB2 and an array of RTKs from outside of the EGFR family. Paradoxically, pertuzumab also acts as an artificial ligand to promote ERBB2 activation and ERK signalling, through allosteric activation by a subset of these non-canonical RTKs. However, this unexpected activation mechanism also increases the sensitivity of the receptor network to the ERBB2 kinase inhibitor lapatinib, which in combination with pertuzumab, displays a synergistic effect in single-agent resistant cell lines and PDX models. The interaction of ERBB2 with a number of non-canonical RTKs activates a compensatory signalling response following treatment with pertuzumab, although a counter-intuitive combination of ERBB2 antibody therapy and a kinase inhibitor can overcome this innate therapeutic resistance.
AbstractList Abstract Background The oncogenic receptor tyrosine kinase (RTK) ERBB2 is known to dimerize with other EGFR family members, particularly ERBB3, through which it potently activates PI3K signalling. Antibody-mediated inhibition of this ERBB2/ERBB3/PI3K axis has been a cornerstone of treatment for ERBB2-amplified breast cancer patients for two decades. However, the lack of response and the rapid onset of relapse in many patients now question the assumption that the ERBB2/ERBB3 heterodimer is the sole relevant effector target of these therapies. Methods Through a systematic protein-protein interaction screen, we have identified and validated alternative RTKs that interact with ERBB2. Using quantitative readouts of signalling pathway activation and cell proliferation, we have examined their influence upon the mechanism of trastuzumab- and pertuzumab-mediated inhibition of cell growth in ERBB2-amplified breast cancer cell lines and a patient-derived xenograft model. Results We now demonstrate that inactivation of ERBB3/PI3K by these therapeutic antibodies is insufficient to inhibit the growth of ERBB2-amplified breast cancer cells. Instead, we show extensive promiscuity between ERBB2 and an array of RTKs from outside of the EGFR family. Paradoxically, pertuzumab also acts as an artificial ligand to promote ERBB2 activation and ERK signalling, through allosteric activation by a subset of these non-canonical RTKs. However, this unexpected activation mechanism also increases the sensitivity of the receptor network to the ERBB2 kinase inhibitor lapatinib, which in combination with pertuzumab, displays a synergistic effect in single-agent resistant cell lines and PDX models. Conclusions The interaction of ERBB2 with a number of non-canonical RTKs activates a compensatory signalling response following treatment with pertuzumab, although a counter-intuitive combination of ERBB2 antibody therapy and a kinase inhibitor can overcome this innate therapeutic resistance.
The oncogenic receptor tyrosine kinase (RTK) ERBB2 is known to dimerize with other EGFR family members, particularly ERBB3, through which it potently activates PI3K signalling. Antibody-mediated inhibition of this ERBB2/ERBB3/PI3K axis has been a cornerstone of treatment for ERBB2-amplified breast cancer patients for two decades. However, the lack of response and the rapid onset of relapse in many patients now question the assumption that the ERBB2/ERBB3 heterodimer is the sole relevant effector target of these therapies. Through a systematic protein-protein interaction screen, we have identified and validated alternative RTKs that interact with ERBB2. Using quantitative readouts of signalling pathway activation and cell proliferation, we have examined their influence upon the mechanism of trastuzumab- and pertuzumab-mediated inhibition of cell growth in ERBB2-amplified breast cancer cell lines and a patient-derived xenograft model. We now demonstrate that inactivation of ERBB3/PI3K by these therapeutic antibodies is insufficient to inhibit the growth of ERBB2-amplified breast cancer cells. Instead, we show extensive promiscuity between ERBB2 and an array of RTKs from outside of the EGFR family. Paradoxically, pertuzumab also acts as an artificial ligand to promote ERBB2 activation and ERK signalling, through allosteric activation by a subset of these non-canonical RTKs. However, this unexpected activation mechanism also increases the sensitivity of the receptor network to the ERBB2 kinase inhibitor lapatinib, which in combination with pertuzumab, displays a synergistic effect in single-agent resistant cell lines and PDX models. The interaction of ERBB2 with a number of non-canonical RTKs activates a compensatory signalling response following treatment with pertuzumab, although a counter-intuitive combination of ERBB2 antibody therapy and a kinase inhibitor can overcome this innate therapeutic resistance.
The oncogenic receptor tyrosine kinase (RTK) ERBB2 is known to dimerize with other EGFR family members, particularly ERBB3, through which it potently activates PI3K signalling. Antibody-mediated inhibition of this ERBB2/ERBB3/PI3K axis has been a cornerstone of treatment for ERBB2-amplified breast cancer patients for two decades. However, the lack of response and the rapid onset of relapse in many patients now question the assumption that the ERBB2/ERBB3 heterodimer is the sole relevant effector target of these therapies. Through a systematic protein-protein interaction screen, we have identified and validated alternative RTKs that interact with ERBB2. Using quantitative readouts of signalling pathway activation and cell proliferation, we have examined their influence upon the mechanism of trastuzumab- and pertuzumab-mediated inhibition of cell growth in ERBB2-amplified breast cancer cell lines and a patient-derived xenograft model. We now demonstrate that inactivation of ERBB3/PI3K by these therapeutic antibodies is insufficient to inhibit the growth of ERBB2-amplified breast cancer cells. Instead, we show extensive promiscuity between ERBB2 and an array of RTKs from outside of the EGFR family. Paradoxically, pertuzumab also acts as an artificial ligand to promote ERBB2 activation and ERK signalling, through allosteric activation by a subset of these non-canonical RTKs. However, this unexpected activation mechanism also increases the sensitivity of the receptor network to the ERBB2 kinase inhibitor lapatinib, which in combination with pertuzumab, displays a synergistic effect in single-agent resistant cell lines and PDX models. The interaction of ERBB2 with a number of non-canonical RTKs activates a compensatory signalling response following treatment with pertuzumab, although a counter-intuitive combination of ERBB2 antibody therapy and a kinase inhibitor can overcome this innate therapeutic resistance.
BACKGROUNDThe oncogenic receptor tyrosine kinase (RTK) ERBB2 is known to dimerize with other EGFR family members, particularly ERBB3, through which it potently activates PI3K signalling. Antibody-mediated inhibition of this ERBB2/ERBB3/PI3K axis has been a cornerstone of treatment for ERBB2-amplified breast cancer patients for two decades. However, the lack of response and the rapid onset of relapse in many patients now question the assumption that the ERBB2/ERBB3 heterodimer is the sole relevant effector target of these therapies. METHODSThrough a systematic protein-protein interaction screen, we have identified and validated alternative RTKs that interact with ERBB2. Using quantitative readouts of signalling pathway activation and cell proliferation, we have examined their influence upon the mechanism of trastuzumab- and pertuzumab-mediated inhibition of cell growth in ERBB2-amplified breast cancer cell lines and a patient-derived xenograft model. RESULTSWe now demonstrate that inactivation of ERBB3/PI3K by these therapeutic antibodies is insufficient to inhibit the growth of ERBB2-amplified breast cancer cells. Instead, we show extensive promiscuity between ERBB2 and an array of RTKs from outside of the EGFR family. Paradoxically, pertuzumab also acts as an artificial ligand to promote ERBB2 activation and ERK signalling, through allosteric activation by a subset of these non-canonical RTKs. However, this unexpected activation mechanism also increases the sensitivity of the receptor network to the ERBB2 kinase inhibitor lapatinib, which in combination with pertuzumab, displays a synergistic effect in single-agent resistant cell lines and PDX models. CONCLUSIONSThe interaction of ERBB2 with a number of non-canonical RTKs activates a compensatory signalling response following treatment with pertuzumab, although a counter-intuitive combination of ERBB2 antibody therapy and a kinase inhibitor can overcome this innate therapeutic resistance.
Background The oncogenic receptor tyrosine kinase (RTK) ERBB2 is known to dimerize with other EGFR family members, particularly ERBB3, through which it potently activates PI3K signalling. Antibody-mediated inhibition of this ERBB2/ERBB3/PI3K axis has been a cornerstone of treatment for ERBB2-amplified breast cancer patients for two decades. However, the lack of response and the rapid onset of relapse in many patients now question the assumption that the ERBB2/ERBB3 heterodimer is the sole relevant effector target of these therapies. Methods Through a systematic protein-protein interaction screen, we have identified and validated alternative RTKs that interact with ERBB2. Using quantitative readouts of signalling pathway activation and cell proliferation, we have examined their influence upon the mechanism of trastuzumab- and pertuzumab-mediated inhibition of cell growth in ERBB2-amplified breast cancer cell lines and a patient-derived xenograft model. Results We now demonstrate that inactivation of ERBB3/PI3K by these therapeutic antibodies is insufficient to inhibit the growth of ERBB2-amplified breast cancer cells. Instead, we show extensive promiscuity between ERBB2 and an array of RTKs from outside of the EGFR family. Paradoxically, pertuzumab also acts as an artificial ligand to promote ERBB2 activation and ERK signalling, through allosteric activation by a subset of these non-canonical RTKs. However, this unexpected activation mechanism also increases the sensitivity of the receptor network to the ERBB2 kinase inhibitor lapatinib, which in combination with pertuzumab, displays a synergistic effect in single-agent resistant cell lines and PDX models. Conclusions The interaction of ERBB2 with a number of non-canonical RTKs activates a compensatory signalling response following treatment with pertuzumab, although a counter-intuitive combination of ERBB2 antibody therapy and a kinase inhibitor can overcome this innate therapeutic resistance.
Background The oncogenic receptor tyrosine kinase (RTK) ERBB2 is known to dimerize with other EGFR family members, particularly ERBB3, through which it potently activates PI3K signalling. Antibody-mediated inhibition of this ERBB2/ERBB3/PI3K axis has been a cornerstone of treatment for ERBB2-amplified breast cancer patients for two decades. However, the lack of response and the rapid onset of relapse in many patients now question the assumption that the ERBB2/ERBB3 heterodimer is the sole relevant effector target of these therapies. Methods Through a systematic protein-protein interaction screen, we have identified and validated alternative RTKs that interact with ERBB2. Using quantitative readouts of signalling pathway activation and cell proliferation, we have examined their influence upon the mechanism of trastuzumab- and pertuzumab-mediated inhibition of cell growth in ERBB2-amplified breast cancer cell lines and a patient-derived xenograft model. Results We now demonstrate that inactivation of ERBB3/PI3K by these therapeutic antibodies is insufficient to inhibit the growth of ERBB2-amplified breast cancer cells. Instead, we show extensive promiscuity between ERBB2 and an array of RTKs from outside of the EGFR family. Paradoxically, pertuzumab also acts as an artificial ligand to promote ERBB2 activation and ERK signalling, through allosteric activation by a subset of these non-canonical RTKs. However, this unexpected activation mechanism also increases the sensitivity of the receptor network to the ERBB2 kinase inhibitor lapatinib, which in combination with pertuzumab, displays a synergistic effect in single-agent resistant cell lines and PDX models. Conclusions The interaction of ERBB2 with a number of non-canonical RTKs activates a compensatory signalling response following treatment with pertuzumab, although a counter-intuitive combination of ERBB2 antibody therapy and a kinase inhibitor can overcome this innate therapeutic resistance. Keywords: ERBB2, Pertuzumab, Receptor tyrosine kinases, Breast cancer, Heterodimers
ArticleNumber 43
Audience Academic
Author Nobis, Max
Cox, Thomas R
Lim, Elgene
Munoz, Amaya Garcia
Hastings, Jordan F
Watkins, D Neil
Murphy, Kendelle J
Kennedy, Sean P
Saunders, Darren N
Portman, Neil
Miladinovic, Dushan
Williams, James T
Kolch, Walter
Cadell, Antonia L
Latham, Sharissa L
Han, Jeremy Z R
O'Donnell, Yolande E I
Shearer, Robert F
Croucher, David R
Timpson, Paul
Marriott, Gabriella R
Author_xml – sequence: 1
  givenname: Sean P
  surname: Kennedy
  fullname: Kennedy, Sean P
  organization: Systems Biology Ireland, University College Dublin, Belfield, Dublin 4, Ireland
– sequence: 2
  givenname: Jeremy Z R
  surname: Han
  fullname: Han, Jeremy Z R
  organization: The Kinghorn Cancer Centre, Garvan Institute of Medical Research, 370 Victoria St, Darlinghurst, Sydney, NSW, 2010, Australia
– sequence: 3
  givenname: Neil
  surname: Portman
  fullname: Portman, Neil
  organization: St Vincent's Hospital Clinical School, University of New South Wales, Sydney, NSW, 2052, Australia
– sequence: 4
  givenname: Max
  surname: Nobis
  fullname: Nobis, Max
  organization: The Kinghorn Cancer Centre, Garvan Institute of Medical Research, 370 Victoria St, Darlinghurst, Sydney, NSW, 2010, Australia
– sequence: 5
  givenname: Jordan F
  surname: Hastings
  fullname: Hastings, Jordan F
  organization: The Kinghorn Cancer Centre, Garvan Institute of Medical Research, 370 Victoria St, Darlinghurst, Sydney, NSW, 2010, Australia
– sequence: 6
  givenname: Kendelle J
  surname: Murphy
  fullname: Murphy, Kendelle J
  organization: The Kinghorn Cancer Centre, Garvan Institute of Medical Research, 370 Victoria St, Darlinghurst, Sydney, NSW, 2010, Australia
– sequence: 7
  givenname: Sharissa L
  surname: Latham
  fullname: Latham, Sharissa L
  organization: The Kinghorn Cancer Centre, Garvan Institute of Medical Research, 370 Victoria St, Darlinghurst, Sydney, NSW, 2010, Australia
– sequence: 8
  givenname: Antonia L
  surname: Cadell
  fullname: Cadell, Antonia L
  organization: The Kinghorn Cancer Centre, Garvan Institute of Medical Research, 370 Victoria St, Darlinghurst, Sydney, NSW, 2010, Australia
– sequence: 9
  givenname: Dushan
  surname: Miladinovic
  fullname: Miladinovic, Dushan
  organization: The Kinghorn Cancer Centre, Garvan Institute of Medical Research, 370 Victoria St, Darlinghurst, Sydney, NSW, 2010, Australia
– sequence: 10
  givenname: Gabriella R
  surname: Marriott
  fullname: Marriott, Gabriella R
  organization: The Kinghorn Cancer Centre, Garvan Institute of Medical Research, 370 Victoria St, Darlinghurst, Sydney, NSW, 2010, Australia
– sequence: 11
  givenname: Yolande E I
  surname: O'Donnell
  fullname: O'Donnell, Yolande E I
  organization: The Kinghorn Cancer Centre, Garvan Institute of Medical Research, 370 Victoria St, Darlinghurst, Sydney, NSW, 2010, Australia
– sequence: 12
  givenname: Robert F
  surname: Shearer
  fullname: Shearer, Robert F
  organization: The Kinghorn Cancer Centre, Garvan Institute of Medical Research, 370 Victoria St, Darlinghurst, Sydney, NSW, 2010, Australia
– sequence: 13
  givenname: James T
  surname: Williams
  fullname: Williams, James T
  organization: School of Medicine, University of Notre Dame, Sydney, NSW, 2011, Australia
– sequence: 14
  givenname: Amaya Garcia
  surname: Munoz
  fullname: Munoz, Amaya Garcia
  organization: Systems Biology Ireland, University College Dublin, Belfield, Dublin 4, Ireland
– sequence: 15
  givenname: Thomas R
  surname: Cox
  fullname: Cox, Thomas R
  organization: St Vincent's Hospital Clinical School, University of New South Wales, Sydney, NSW, 2052, Australia
– sequence: 16
  givenname: D Neil
  surname: Watkins
  fullname: Watkins, D Neil
  organization: St Vincent's Hospital Clinical School, University of New South Wales, Sydney, NSW, 2052, Australia
– sequence: 17
  givenname: Darren N
  surname: Saunders
  fullname: Saunders, Darren N
  organization: School of Medical Sciences, University of New South Wales, Sydney, NSW, 2025, Australia
– sequence: 18
  givenname: Paul
  surname: Timpson
  fullname: Timpson, Paul
  organization: St Vincent's Hospital Clinical School, University of New South Wales, Sydney, NSW, 2052, Australia
– sequence: 19
  givenname: Elgene
  surname: Lim
  fullname: Lim, Elgene
  organization: St Vincent's Hospital Clinical School, University of New South Wales, Sydney, NSW, 2052, Australia
– sequence: 20
  givenname: Walter
  surname: Kolch
  fullname: Kolch, Walter
  organization: School of Medicine and Medical Science, University College Dublin, Belfield, Dublin 4, Ireland
– sequence: 21
  givenname: David R
  orcidid: 0000-0003-4965-8674
  surname: Croucher
  fullname: Croucher, David R
  email: d.croucher@garvan.org.au, d.croucher@garvan.org.au, d.croucher@garvan.org.au
  organization: School of Medicine and Medical Science, University College Dublin, Belfield, Dublin 4, Ireland. d.croucher@garvan.org.au
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30898150$$D View this record in MEDLINE/PubMed
BookMark eNptkl9rFDEUxQep2D_6AXyRAV98mZqbTDKZF6EttRYKglTwLWSTO7tZdpI1yS6sn95Mt9auSB4mZM75Xe7hnFZHPnisqrdAzgGk-JiAES4bAn0DQLtm96I6gVbwhrf0x9Gz-3F1mtKSEOgkl6-qY0ZkL4GTk2p7r-Mcs_Pzeh3D6JLZhE2qF5gxButGjO6Xzi74OmwxmjBiqp33OmMdMbmUtTdY51Bff7u8pPWBw_mFm7kc4mSpZxF1yrWZDPF19XLQq4RvHr9n1ffP1_dXX5q7rze3Vxd3jeGC5EYj0bYz0tBWWIrMSt6TbtZKSoQEBIODwB4ASRGJQVvageS060UL2vKOnVW3e64NeqnW0Y067lTQTj08hDhXOmZnVqgEMz3TFPoCa60FDdD3YiiDB8n0zBbWpz1rvZmNaA36HPXqAHr4x7uFmoetEi3tJSMF8OEREMPPDaasprxxtdIeS-iqzBa8bAasSN__I12GTfQlKkUpQNv1rWj_qua6LOD8EMpcM0HVBZfAJC15FNX5f1TlWBydKY0aXHk_MMDeYGJIKeLwtCMQNRVP7YunSvHUVDy1K553z8N5cvxpGvsNF7HW5A
CitedBy_id crossref_primary_10_1038_s41568_023_00634_x
crossref_primary_10_1016_j_celrep_2021_110285
crossref_primary_10_1002_stem_3381
crossref_primary_10_1186_s12964_021_00798_9
crossref_primary_10_1073_pnas_2006429117
crossref_primary_10_1016_j_ceb_2021_04_007
crossref_primary_10_1016_j_ejca_2020_11_045
crossref_primary_10_1158_1078_0432_CCR_21_2827
crossref_primary_10_3390_ijms21239008
crossref_primary_10_1038_s41586_022_05194_y
crossref_primary_10_1007_s12539_023_00568_w
crossref_primary_10_3389_fonc_2022_840241
crossref_primary_10_7554_eLife_53367
crossref_primary_10_1186_s13046_022_02389_z
crossref_primary_10_1073_pnas_2302937120
crossref_primary_10_1038_s41420_020_00337_4
crossref_primary_10_1126_sciadv_abp8314
crossref_primary_10_1021_acs_jmedchem_9b02001
crossref_primary_10_1038_s41598_021_86860_5
crossref_primary_10_1124_pharmrev_123_000906
crossref_primary_10_1038_s41598_019_55146_2
crossref_primary_10_1111_cas_14034
crossref_primary_10_1016_j_drup_2024_101078
crossref_primary_10_1016_j_celrep_2023_112670
crossref_primary_10_1007_s10555_020_09922_6
crossref_primary_10_1016_j_pharmthera_2020_107677
Cites_doi 10.1016/j.cell.2006.05.013
10.1091/mbc.e10-03-0185
10.1021/ja046699g
10.18632/oncotarget.3296
10.1186/s12943-018-0797-x
10.1126/science.1075762
10.1016/S1535-6108(02)00097-1
10.1007/BF00694752
10.1590/0001-3765201620150178
10.1038/nsb0394-157
10.1074/jbc.M108681200
10.1016/S1470-2045(14)70320-1
10.1021/jm801586s
10.1016/j.cell.2010.06.011
10.1158/0008-5472.CAN-12-1472
10.1016/j.cell.2014.04.039
10.1073/pnas.1104778108
10.1016/j.str.2007.12.016
10.1128/MCB.15.10.5770
10.1126/science.3798106
10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V
10.1126/scisignal.aab0990
10.1186/s13058-017-0806-9
10.1200/JCO.2013.54.5384
10.1056/NEJMoa064320
10.1073/pnas.1537685100
10.1056/NEJMoa1413513
10.1016/S1535-6108(04)00083-2
10.1056/NEJMoa1209124
10.1038/nature09627
10.1158/0008-5472.CAN-11-3747
10.1242/jcs.033399
10.1128/MCB.21.19.6387-6394.2001
10.1074/jbc.274.13.8865
10.1007/978-1-59745-542-8_17
10.1038/nm.2454
10.3389/fcell.2016.00088
10.1038/35052073
10.1158/0008-5472.CAN-10-2527
10.1200/JCO.1989.7.8.1120
10.1126/scisignal.aaf0793
10.1016/S0140-6736(16)32616-2
10.1016/S1470-2045(16)00163-7
10.1074/jbc.275.8.5388
10.1158/0008-5472.CAN-08-0380
10.3389/fonc.2018.00156
10.1056/NEJMx170011
10.1016/j.jmb.2014.10.007
10.1200/JCO.2018.79.2697
ContentType Journal Article
Copyright COPYRIGHT 2019 BioMed Central Ltd.
2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s). 2019
Copyright_xml – notice: COPYRIGHT 2019 BioMed Central Ltd.
– notice: 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s). 2019
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
3V.
7TO
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s13058-019-1127-y
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
ProQuest Central (Corporate)
Oncogenes and Growth Factors Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Publicly Available Content Database
Oncogenes and Growth Factors Abstracts
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
AIDS and Cancer Research Abstracts
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList

MEDLINE
MEDLINE - Academic
Publicly Available Content Database

Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: 7X7
  name: Health & Medical Collection
  url: https://search.proquest.com/healthcomplete
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
EISSN 1465-542X
EndPage 43
ExternalDocumentID oai_doaj_org_article_63c93a219e074dd1a11996f46df83abd
A581382271
10_1186_s13058_019_1127_y
30898150
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations United States--US
GeographicLocations_xml – name: United States--US
GrantInformation_xml – fundername: ;
  grantid: 13/FRL/1-02
– fundername: ;
  grantid: CCRC13GAL
– fundername: ;
  grantid: 11/SIRG/B2157; 14/IA/2395
GroupedDBID ---
04C
0R~
23N
2WC
4.4
53G
5GY
5VS
6J9
7X7
8FI
8FJ
AAFWJ
AAJSJ
AAWTL
ABUWG
ACGFO
ACGFS
ACJQM
ACMJI
ACPRK
ACRMQ
ADBBV
ADFRT
ADINQ
ADUKV
AENEX
AFKRA
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIAM
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BMSDO
BPHCQ
BVXVI
C24
C6C
CCPQU
CGR
CS3
CUY
CVF
DIK
DU5
E3Z
EBD
EBLON
EBS
ECM
EIF
EIHBH
EJD
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
ICW
IHR
INH
INR
ITC
KQ8
NPM
O5R
O5S
OK1
P2P
PGMZT
PIMPY
PQQKQ
PROAC
RBZ
ROL
RPM
RSV
SBL
SOJ
TR2
U2A
UKHRP
WOQ
AAYXX
CITATION
3V.
7TO
7XB
8FK
AZQEC
DWQXO
H94
K9.
PQEST
PQUKI
PRINS
7X8
5PM
AFPKN
ID FETCH-LOGICAL-c560t-ae0ad7c8c246d2e3d85907b4820681e1cef6e911e07c86fad27185279641ad573
IEDL.DBID RPM
ISSN 1465-542X
1465-5411
IngestDate Tue Oct 22 15:14:36 EDT 2024
Tue Sep 17 21:19:17 EDT 2024
Fri Oct 25 00:34:09 EDT 2024
Thu Oct 10 17:05:24 EDT 2024
Tue Nov 19 21:02:14 EST 2024
Tue Nov 12 23:30:33 EST 2024
Thu Nov 21 23:22:54 EST 2024
Wed Oct 16 00:46:17 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Heterodimers
Breast cancer
Pertuzumab
Receptor tyrosine kinases
ERBB2
Language English
License Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c560t-ae0ad7c8c246d2e3d85907b4820681e1cef6e911e07c86fad27185279641ad573
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0003-4965-8674
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429830/
PMID 30898150
PQID 2211479464
PQPubID 2034567
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_63c93a219e074dd1a11996f46df83abd
pubmedcentral_primary_oai_pubmedcentral_nih_gov_6429830
proquest_miscellaneous_2196520613
proquest_journals_2211479464
gale_infotracmisc_A581382271
gale_infotracacademiconefile_A581382271
crossref_primary_10_1186_s13058_019_1127_y
pubmed_primary_30898150
PublicationCentury 2000
PublicationDate 2019-03-21
PublicationDateYYYYMMDD 2019-03-21
PublicationDate_xml – month: 03
  year: 2019
  text: 2019-03-21
  day: 21
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Breast cancer research : BCR
PublicationTitleAlternate Breast Cancer Res
PublicationYear 2019
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References Y Saito (1127_CR46) 2001; 21
SM Swain (1127_CR7) 2015; 372
T Holbro (1127_CR16) 2003; 100
P Sawma (1127_CR43) 2014; 426
R Worthylake (1127_CR15) 1999; 274
G Manning (1127_CR33) 2002; 298
MA Lemmon (1127_CR13) 2010; 141
RH Tao (1127_CR31) 2008; 121
D Fey (1127_CR27) 2015; 8
E Azambuja de (1127_CR10) 2014; 15
D Cameron (1127_CR4) 2017; 389
JM Mendrola (1127_CR42) 2002; 277
DR Croucher (1127_CR23) 2016; 9
S Verma (1127_CR48) 2012; 367
MT Herrera Abreu (1127_CR25) 2011; 22
Y Yarden (1127_CR14) 2001; 2
GM Schroeder (1127_CR38) 2009; 52
DJ Slamon (1127_CR1) 1987; 235
CE Geyer (1127_CR9) 2006; 355
E Tagliabue (1127_CR47) 2000; 275
A Kiyatkin (1127_CR28) 2009; 536
R Butti (1127_CR34) 2018; 17
WY Leung (1127_CR40) 2015; 6
DJ Riese 2nd (1127_CR20) 1998; 20
L Gianni (1127_CR8) 2016; 17
J Baselga (1127_CR11) 2014; 32
M Debiasi (1127_CR22) 2018; 8
G Bianchini (1127_CR12) 2017; 19
AB Turke (1127_CR37) 2012; 72
DR Croucher (1127_CR26) 2013; 73
CM Johannessen (1127_CR24) 2010; 468
SP Kennedy (1127_CR21) 2016; 4
SR Oakes (1127_CR30) 2012; 109
X Zhang (1127_CR45) 2006; 125
MC Franklin (1127_CR5) 2004; 5
HS Earp (1127_CR19) 1995; 35
ST Lee-Hoeflich (1127_CR17) 2008; 68
DJ Riese 2nd (1127_CR18) 1995; 15
WK You (1127_CR39) 2011; 71
SH Giordano (1127_CR49) 2018; 36
S Regot (1127_CR36) 2014; 157
TJ Magliery (1127_CR32) 2005; 127
S Richard (1127_CR3) 2016; 88
C Qiu (1127_CR44) 2008; 16
DB Agus (1127_CR35) 2002; 2
YS DeRose (1127_CR29) 2011; 17
1127_CR6
AK Tandon (1127_CR2) 1989; 7
MA Lemmon (1127_CR41) 1994; 1
References_xml – volume: 125
  start-page: 1137
  issue: 6
  year: 2006
  ident: 1127_CR45
  publication-title: Cell
  doi: 10.1016/j.cell.2006.05.013
  contributor:
    fullname: X Zhang
– volume: 22
  start-page: 105
  issue: 1
  year: 2011
  ident: 1127_CR25
  publication-title: Mol Biol Cell
  doi: 10.1091/mbc.e10-03-0185
  contributor:
    fullname: MT Herrera Abreu
– volume: 127
  start-page: 146
  issue: 1
  year: 2005
  ident: 1127_CR32
  publication-title: J Am Chem Soc
  doi: 10.1021/ja046699g
  contributor:
    fullname: TJ Magliery
– volume: 6
  start-page: 5678
  issue: 8
  year: 2015
  ident: 1127_CR40
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.3296
  contributor:
    fullname: WY Leung
– volume: 17
  start-page: 34
  issue: 1
  year: 2018
  ident: 1127_CR34
  publication-title: Mol Cancer
  doi: 10.1186/s12943-018-0797-x
  contributor:
    fullname: R Butti
– volume: 298
  start-page: 1912
  issue: 5600
  year: 2002
  ident: 1127_CR33
  publication-title: Science
  doi: 10.1126/science.1075762
  contributor:
    fullname: G Manning
– volume: 2
  start-page: 127
  issue: 2
  year: 2002
  ident: 1127_CR35
  publication-title: Cancer Cell
  doi: 10.1016/S1535-6108(02)00097-1
  contributor:
    fullname: DB Agus
– volume: 35
  start-page: 115
  issue: 1
  year: 1995
  ident: 1127_CR19
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/BF00694752
  contributor:
    fullname: HS Earp
– volume: 88
  start-page: 565
  issue: Suppl 1
  year: 2016
  ident: 1127_CR3
  publication-title: An Acad Bras Cienc
  doi: 10.1590/0001-3765201620150178
  contributor:
    fullname: S Richard
– volume: 1
  start-page: 157
  issue: 3
  year: 1994
  ident: 1127_CR41
  publication-title: Nat Struct Biol
  doi: 10.1038/nsb0394-157
  contributor:
    fullname: MA Lemmon
– volume: 277
  start-page: 4704
  issue: 7
  year: 2002
  ident: 1127_CR42
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M108681200
  contributor:
    fullname: JM Mendrola
– volume: 15
  start-page: 1137
  issue: 10
  year: 2014
  ident: 1127_CR10
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(14)70320-1
  contributor:
    fullname: E Azambuja de
– volume: 52
  start-page: 1251
  issue: 5
  year: 2009
  ident: 1127_CR38
  publication-title: J Med Chem
  doi: 10.1021/jm801586s
  contributor:
    fullname: GM Schroeder
– volume: 141
  start-page: 1117
  issue: 7
  year: 2010
  ident: 1127_CR13
  publication-title: Cell
  doi: 10.1016/j.cell.2010.06.011
  contributor:
    fullname: MA Lemmon
– volume: 73
  start-page: 1969
  issue: 6
  year: 2013
  ident: 1127_CR26
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-12-1472
  contributor:
    fullname: DR Croucher
– volume: 157
  start-page: 1724
  issue: 7
  year: 2014
  ident: 1127_CR36
  publication-title: Cell
  doi: 10.1016/j.cell.2014.04.039
  contributor:
    fullname: S Regot
– volume: 109
  start-page: 2766
  issue: 8
  year: 2012
  ident: 1127_CR30
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1104778108
  contributor:
    fullname: SR Oakes
– volume: 16
  start-page: 460
  issue: 3
  year: 2008
  ident: 1127_CR44
  publication-title: Structure
  doi: 10.1016/j.str.2007.12.016
  contributor:
    fullname: C Qiu
– volume: 15
  start-page: 5770
  issue: 10
  year: 1995
  ident: 1127_CR18
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.15.10.5770
  contributor:
    fullname: DJ Riese 2nd
– volume: 235
  start-page: 177
  issue: 4785
  year: 1987
  ident: 1127_CR1
  publication-title: Science
  doi: 10.1126/science.3798106
  contributor:
    fullname: DJ Slamon
– volume: 20
  start-page: 41
  issue: 1
  year: 1998
  ident: 1127_CR20
  publication-title: BioEssays
  doi: 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V
  contributor:
    fullname: DJ Riese 2nd
– volume: 8
  start-page: ra130
  issue: 408
  year: 2015
  ident: 1127_CR27
  publication-title: Sci Signal
  doi: 10.1126/scisignal.aab0990
  contributor:
    fullname: D Fey
– volume: 19
  start-page: 16
  issue: 1
  year: 2017
  ident: 1127_CR12
  publication-title: Breast Cancer Res
  doi: 10.1186/s13058-017-0806-9
  contributor:
    fullname: G Bianchini
– volume: 32
  start-page: 3753
  issue: 33
  year: 2014
  ident: 1127_CR11
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2013.54.5384
  contributor:
    fullname: J Baselga
– volume: 355
  start-page: 2733
  issue: 26
  year: 2006
  ident: 1127_CR9
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa064320
  contributor:
    fullname: CE Geyer
– volume: 100
  start-page: 8933
  issue: 15
  year: 2003
  ident: 1127_CR16
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1537685100
  contributor:
    fullname: T Holbro
– volume: 372
  start-page: 724
  issue: 8
  year: 2015
  ident: 1127_CR7
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1413513
  contributor:
    fullname: SM Swain
– volume: 5
  start-page: 317
  issue: 4
  year: 2004
  ident: 1127_CR5
  publication-title: Cancer Cell
  doi: 10.1016/S1535-6108(04)00083-2
  contributor:
    fullname: MC Franklin
– volume: 367
  start-page: 1783
  issue: 19
  year: 2012
  ident: 1127_CR48
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1209124
  contributor:
    fullname: S Verma
– volume: 468
  start-page: 968
  issue: 7326
  year: 2010
  ident: 1127_CR24
  publication-title: Nature
  doi: 10.1038/nature09627
  contributor:
    fullname: CM Johannessen
– volume: 72
  start-page: 3228
  issue: 13
  year: 2012
  ident: 1127_CR37
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-11-3747
  contributor:
    fullname: AB Turke
– volume: 121
  start-page: 3207
  year: 2008
  ident: 1127_CR31
  publication-title: J Cell Sci
  doi: 10.1242/jcs.033399
  contributor:
    fullname: RH Tao
– volume: 21
  start-page: 6387
  issue: 19
  year: 2001
  ident: 1127_CR46
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.21.19.6387-6394.2001
  contributor:
    fullname: Y Saito
– volume: 274
  start-page: 8865
  issue: 13
  year: 1999
  ident: 1127_CR15
  publication-title: J Biol Chem
  doi: 10.1074/jbc.274.13.8865
  contributor:
    fullname: R Worthylake
– volume: 536
  start-page: 149
  year: 2009
  ident: 1127_CR28
  publication-title: Methods Mol Biol
  doi: 10.1007/978-1-59745-542-8_17
  contributor:
    fullname: A Kiyatkin
– volume: 17
  start-page: 1514
  issue: 11
  year: 2011
  ident: 1127_CR29
  publication-title: Nat Med
  doi: 10.1038/nm.2454
  contributor:
    fullname: YS DeRose
– volume: 4
  start-page: 88
  year: 2016
  ident: 1127_CR21
  publication-title: Front Cell Dev Biol
  doi: 10.3389/fcell.2016.00088
  contributor:
    fullname: SP Kennedy
– volume: 2
  start-page: 127
  issue: 2
  year: 2001
  ident: 1127_CR14
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/35052073
  contributor:
    fullname: Y Yarden
– volume: 71
  start-page: 4758
  issue: 14
  year: 2011
  ident: 1127_CR39
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-10-2527
  contributor:
    fullname: WK You
– volume: 7
  start-page: 1120
  issue: 8
  year: 1989
  ident: 1127_CR2
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.1989.7.8.1120
  contributor:
    fullname: AK Tandon
– volume: 9
  start-page: ra69
  issue: 436
  year: 2016
  ident: 1127_CR23
  publication-title: Sci Signal
  doi: 10.1126/scisignal.aaf0793
  contributor:
    fullname: DR Croucher
– volume: 389
  start-page: 1195
  issue: 10075
  year: 2017
  ident: 1127_CR4
  publication-title: Lancet
  doi: 10.1016/S0140-6736(16)32616-2
  contributor:
    fullname: D Cameron
– volume: 17
  start-page: 791
  issue: 6
  year: 2016
  ident: 1127_CR8
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(16)00163-7
  contributor:
    fullname: L Gianni
– volume: 275
  start-page: 5388
  issue: 8
  year: 2000
  ident: 1127_CR47
  publication-title: J Biol Chem
  doi: 10.1074/jbc.275.8.5388
  contributor:
    fullname: E Tagliabue
– volume: 68
  start-page: 5878
  issue: 14
  year: 2008
  ident: 1127_CR17
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-08-0380
  contributor:
    fullname: ST Lee-Hoeflich
– volume: 8
  start-page: 156
  year: 2018
  ident: 1127_CR22
  publication-title: Front Oncol
  doi: 10.3389/fonc.2018.00156
  contributor:
    fullname: M Debiasi
– ident: 1127_CR6
  doi: 10.1056/NEJMx170011
– volume: 426
  start-page: 4099
  issue: 24
  year: 2014
  ident: 1127_CR43
  publication-title: J Mol Biol
  doi: 10.1016/j.jmb.2014.10.007
  contributor:
    fullname: P Sawma
– volume: 36
  start-page: 2736
  issue: 26
  year: 2018
  ident: 1127_CR49
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2018.79.2697
  contributor:
    fullname: SH Giordano
SSID ssj0017858
Score 2.4728558
Snippet The oncogenic receptor tyrosine kinase (RTK) ERBB2 is known to dimerize with other EGFR family members, particularly ERBB3, through which it potently activates...
Background The oncogenic receptor tyrosine kinase (RTK) ERBB2 is known to dimerize with other EGFR family members, particularly ERBB3, through which it...
BACKGROUNDThe oncogenic receptor tyrosine kinase (RTK) ERBB2 is known to dimerize with other EGFR family members, particularly ERBB3, through which it potently...
Abstract Background The oncogenic receptor tyrosine kinase (RTK) ERBB2 is known to dimerize with other EGFR family members, particularly ERBB3, through which...
SourceID doaj
pubmedcentral
proquest
gale
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 43
SubjectTerms 1-Phosphatidylinositol 3-kinase
Allosteric properties
Animals
Antibodies
Antibodies, Monoclonal, Humanized - pharmacology
Biomarkers
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - metabolism
Breast Neoplasms - pathology
Cancer cells
Cancer patients
Cancer therapies
Cell activation
Cell culture
Cell Line, Tumor
Cell proliferation
Chemotherapy
Clinical trials
Dimerization
Disease Models, Animal
Displays (Marketing)
Dose-Response Relationship, Drug
Drug Resistance, Neoplasm
Drug therapy
Enzyme inhibitors
Epidermal growth factor
Epidermal growth factor receptors
ErbB-2 protein
ErbB-3 protein
ERBB2
Extracellular signal-regulated kinase
Family relations
Female
Fluorescent Antibody Technique
Heterodimers
Humans
Immunoglobulins
Immunohistochemistry
Immunotherapy
Kinases
Lapatinib
Ligands
Medical prognosis
Metastasis
Mice
Monoclonal antibodies
Patients
Pertuzumab
Phenols (Class of compounds)
Phosphorylation
Promiscuity
Protein interaction
Protein Kinase Inhibitors - pharmacology
Protein Multimerization
Protein-protein interactions
Protein-tyrosine kinase receptors
Receptor tyrosine kinases
Receptor, ErbB-2 - antagonists & inhibitors
Receptor, ErbB-2 - chemistry
Receptor, ErbB-2 - metabolism
Signal transduction
Signal Transduction - drug effects
Targeted cancer therapy
Trastuzumab
Trastuzumab - pharmacology
Tumor cell lines
Tyrosine
Xenograft Model Antitumor Assays
Xenografts
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Na9wwEB1KDqWX0iT9cJMWFUoLBRNbsmTpuFsSQiE9lARyE7Iksz7UW7JOYf99Z2TvsqaHXnpbLMtr6c1oZqyZJ4CPRrdCNMLkgXZaK-9M7lrv8xCjkzJEUQSqRr75rq7vqm_38v7gqC_KCRvpgceJu1DCG-FQryIauxBKV1LebFup0GrhmpBW34Lvgqlp_6DWUk97mKVWFxtcqSUlbZkc_Ys6386sUCLr_3tJPrBJ83zJAwN09QKeT54jW4xvfAxPYn8Cp4seo-afW_aJpVzO9JH8BJ7eTFvmp_D7NuV6o4Vi-JeIqn_EYJ-tKA1mHTrasBkrMRklc6L8xQ3renxqZBiJk3eJYsGGNbv8sVxyNuvR9auu6ei8HvzJGspvH5inDg8v4e7q8vbrdT4dtpB7dHqG3MXChdprz3FqeRRBS4ybm4r43XUZSx9bFXFlRBi8Vq0LvKa6a6pkLV2QtXgFR_26j2-AycIbZ4rGaRkRfafboFTjKgrNiBAugy-7ybe_Rk4Nm2IRreyIlEWkLCFltxksCZ79jUSHnS6gkNhJSOy_hCSDzwSuJaVFBL2bag_wfYn-yi6kJi5GHFIG57M7CZZ580487KTsG8sxiE5E_VUGH_bN1JMS2PqIqFpOzI2cnKcMXo_StB-SKLTR6JhnUM_kbDbmeUvfrRIVOEaPRovi7f-YpDN4xklDCpHz8hyOhofH-A49rqF5n5TrDy4fK3E
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA96gvgieudHz1MiiIIQrkmaNn2SXbnjEM4HuYN9C2mSun2wPXf3Dva_dybNrlcE35Ym6SadyWQmM_MbQj7UupWykTXz6GktnK2ZbZ1jPgSrlA8y95iNfPm9vLguvi3UIl24rVNY5U4mRkHtB4d35KcCLJWIhl58ufnNsGoUeldTCY2H5BEXcJQDP1eLvcGFhef1mF2kmCo4T15NrsvTNchuhWFcNQONo2LbybkU4fv_FdL3TqlpBOW9I-n8GXmadEk6G4n_nDwI_SE5mvVgR__a0o80RnfGa_ND8vgyOdGPyN1VjP6GM4vCXwKd3S2Y_3SJgTGD79CFM-ZmUgzvhK8T1rTr4a2Bgm2O-iYwCt0M9OzHfC7oZETXL7umwwo-8JM2GPG-oQ4HrF6Q6_Ozq68XLJVfYA7UoA2zIbe-ctqJovQiSK8VWNJNgYjvmgfuQlsGkJUhh05la72oMBMbc1u59aqSL8lBP_ThNaEqd7Wt88ZqFYAfrG59WTa2QGMNIeIy8nn38c3NiLJhonWiSzNSygClDFLKbDMyR_LsOyJAdnwwrH6atN9MKV0tLYhjmF3hPbccw61bWEmrpW18Rj4hcQ1uY6CgsykbAeaLgFhmpjSiM8KSMnIy6YlkmTbv2MOk7b82f5k1I-_3zTgSQ9r6AFQ1ArEcBapTGXk1ctN-STLXtQZVPSPVhM8ma5629N0ygoODPVlrmR__f1pvyBOBvJ9LJvgJOdisbsNb0K42zbu4hf4APYYkpg
  priority: 102
  providerName: ProQuest
Title Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer
URI https://www.ncbi.nlm.nih.gov/pubmed/30898150
https://www.proquest.com/docview/2211479464
https://search.proquest.com/docview/2196520613
https://pubmed.ncbi.nlm.nih.gov/PMC6429830
https://doaj.org/article/63c93a219e074dd1a11996f46df83abd
Volume 21
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swED_aDkpfxtbuw1sXNBgbDNzYlmXLj0lJKYOUEloIexGyJC-GxSlJOsh_vzvFCTF720sIkZRIuW_f704AXwpZcV7yIrSUaU2NLkJdGRNa57QQ1vHIUjXy-C67fUx_TMX0CMSuFsaD9k1ZXzW_51dNPfPYyqe56e9wYv378TX6zIXkUf8YjtH87kL0NnWQS38pJ2oAEYo0jttUZiyz_goVtiDsVhGim5GHmzM45ZEsZExl9wd2ybfv_1dJH1ipLoLywCTdvIKXrS_JBts9v4Yj15zDxaDBOHq-YV-ZR3f6x-bncDpuk-gX8OfBo7_RZjH8SaSzecbwn80IGLOwNaVwtrWZjOCdyJFuxeoGv9UxjM3J30RGYesFG02Gw4R1VtTNrC5rusEH37KSEO9rZmjB8g083owerm_D9vqF0KAbtA61i7TNjTRJmtnEcSsFRtJlSh3fZexi46rMoa50EU7KKm2TnCqxqbY11lbk_C2cNIvGvQcmIlPoIiq1FA75QcvKZlmpUwrWqEVcAN93f7562nbZUD46kZnaEk0h0RQRTW0CGBJ59hOpQbb_YLH8pVo2URk3BdeojnF3qbWxjgluXeFJKsl1aQP4RsRVJMZIQaPbagTcLzXEUgMhqTsjHimAy85MIkt3eMceqhX_lUowrPat-9MAPu-HaSVB2hqHVFUJ9XJMyJ0K4N2Wm_ZH2jFlAHmHzzpn7o6grPjm4K1sfPjvlR_hLCEJiXiYxJdwsl4-u0_oeK3LHorbNO_Bi-Ho7n7S848v8HUy_NnzIvgXE0oyLw
link.rule.ids 230,314,727,780,784,864,885,2102,12056,21388,27924,27925,31719,31720,33744,33745,43310,43805,53791,53793
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwED9BJwEvCDY-AgOMhEBCspbEceI8oRZ1KrBWaOqkvVmO7dA8kIx-IPW_5y5NyyIk3qrYTu3c-Xznu_sdwLtclUIUIueOPK2JNTk3pbXceW-kdF6EjrKRp7N0cpV8vZbX3YXbqgur3MvEVlC7xtId-VmMlkqLhp58uvnFqWoUeVe7Ehp34YiQ0-UAjkbj2ffLgx8hU22FThQHksskijq_ZqTSsxVKb0mBXDlHnSPj297J1AL4_yumb51T_RjKW4fS-SN42GmTbLgj_2O44-tjOBnWaEn_3LL3rI3vbC_Oj-HetHOjn8DveRv_jacWw79ESttNs1mxBYXGNK4iJ84uO5NRgCd-H79iVY1v9Qytc9I4kVXYumHjy9EoZr0RVb2oiopq-OBPVlDM-5pZGrB8Alfn4_nnCe8KMHCLitCaGx8al1ll4yR1sRdOSbSli4Qw31XkI-vL1KO09CF2Skvj4oxysSm7NTJOZuIpDOqm9s-BydDmJg8Lo6RHjjCqdGlamITMNQKJC-Dj_uPrmx3Ohm7tE5XqHaU0UkoTpfQ2gBGR59CRILLbB83yh-52nE6FzYVBgYyzS5yLTEQB1yWupFTCFC6AD0RcTRsZKWhNl4-A8yVILD2UivAZcUkBnPZ6Eln6zXv20J0AWOm_7BrA20MzjaSgttojVXVMaI4xKVQBPNtx02FJIlS5QmU9gKzHZ70191vqatHCg6NFmSsRvvj_tN7A_cl8eqEvvsy-vYQHMe2DUPA4OoXBernxr1DXWhevuw31Bxn6KPw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFD5sHYS-jK3dxVu3aTA2GLixLcuWH5OuobuklNFC34QsyYthcUIug_z7naM4IWZvewuW5Eg5F50TfecTwIdCVpyXvAgtnbSmRhehrowJrXNaCOt4ZKkaeXydXd2l3-7F_cFVXx60b8r6vPk9PW_qicdWzqemv8OJ9W_GFxgzF5JH_bmt-g_hkeCoZLtEvT1AyKW_mhP9gAhFGsftgWYss_4S3bYgBFcRYrCRh5tj6PFIFjKm4vuD3cmT-P_rqg_2qi6O8mBjGj2Bx21EyQbbmT-FB645gdNBg9n0dMM-Mo_x9H-en0Bv3B6ln8KfW48Bx52L4VeitM16tl6yCcFjZramg5xthSYjkCfqpVuyusG3OoYZOkWdqC5sNWOXP4fDhHVG1M2kLmu6xwc_spJw7ytmaMDiGdyNLm8vrsL2EobQYDC0CrWLtM2NNEma2cRxKwXm02VKvO8ydrFxVebQY7oIO2WVtklO9dhU4RprK3L-HI6aWeNeAhORKXQRlVoKh1qhZWWzrNQppWxEFBfA592Pr-Zbrg3lcxSZqa3QFApNkdDUJoAhiWffkWiy_YPZ4pdqlUVl3BRco1PG2aXWxjom0HWFK6kk16UN4BMJV5ExowSNbmsScL5Ei6UGQhJHIy4pgLNOTxJLt3mnHqp1AkuVYHLtCfzTAN7vm2kkAdsah1JVCTE6JhRUBfBiq037Je2UMoC8o2edNXdb0GI8RXhrIa_-e-Q76N18GakfX6-_v4bjhIwl4mESn8HRarF2bzASW5Vvvc39BYZpMhI
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Targeting+promiscuous+heterodimerization+overcomes+innate+resistance+to+ERBB2+dimerization+inhibitors+in+breast+cancer&rft.jtitle=Breast+cancer+research+%3A+BCR&rft.au=Kennedy%2C+Sean+P&rft.au=Han%2C+Jeremy+Z+R&rft.au=Portman%2C+Neil&rft.au=Nobis%2C+Max&rft.date=2019-03-21&rft.eissn=1465-542X&rft.volume=21&rft.issue=1&rft.spage=43&rft.epage=43&rft_id=info:doi/10.1186%2Fs13058-019-1127-y&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1465-542X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1465-542X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1465-542X&client=summon